25 stories mentioning JAZZUpdated 2d ago
Every FINWIRES story that references JAZZ, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Jazz Pharmaceuticals (JAZZ) has an average rating of overweight and mean price target of $259.28, according to analysts polled by FactSet.Price: $234.28, Change: $+5.09, Percent Change: +2.22%
Jazz Pharmaceuticals Public Company (JAZZ) has an average rating of overweight and mean price target of $256.82, according to analysts polled by FactSet.
Jazz Pharmaceuticals (JAZZ) has an average rating of overweight and mean price target of $245.60, according to analysts polled by FactSet.
Jazz Pharmaceuticals (JAZZ) delivered a "strong" Q1 as broad-based growth across its commercial portfolio and pipeline reinforced confidence in the health of the business, RBC Capital Markets said in a report Wednesday.Q1 revenue of about $1.07 billion topped the consensus estimate of $978 million, driven by strength across nearly "all major assets," the report said, adding that the company maintained its 2026 revenue guidance of $4.25 billion to $4.5 billion, though results could exceed that range.Concerns remain around future generic competition for the "oxybate franchise" and competitive pressures in oncology, though the firm believes the company's strong execution provides a cushion against potential "erosion." RBC estimates 2026 sales for Xywav at about $1.73 billion with expected "gradual decline" in later years, according to the report.The report also highlighted the company's "oncology pipeline" as a key focus, citing potential expansion opportunities for Ziihera, strong "initial uptake" for Modeyso, better-than-expected Zepzelca revenue and 15% year-over-year Epidiolex sales growth to $250 million driven by sustained epilepsy-related demand and international expansion.RBC maintained an outperform rating on Jazz Pharmaceuticals and raised its price target to $258 from $195.Price: $223.80, Change: $+11.54, Percent Change: +5.44%
Bruce C Cozadd, Director, on May 01, 2026, sold 6,000 shares in Jazz Pharmaceuticals (JAZZ) for $1,219,980. Following the Form 4 filing with the SEC, Cozadd has control over a total of 378,682 ordinary shares of the company, with 378,682 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1232524/000119321026000011/xslF345X05/edgardoc.xml
Showing 21-25 of 25
